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A single-arm, open-label study to assess the 
immunogenicity, safety, and efficacy of etanercept 
manufactured using the serum-free, high-capacity 
manufacturing process administered to patients with 
rheumatoid arthritis
Introduction
It is a common part of managing the life cycle of a biological drug, as with all medications, to undergo 
revisions to the manufacturing processes (1), all of which are strictly regulated (2). Etanercept (ETN) is a 
dimeric, human recombinant fusion protein that binds specifically to tumor necrosis factor (TNF) and lym-
photoxin, inhibiting their interaction with cell surface receptors (3, 4). ETN has been manufactured using a 
number of processes since its approval in 1998, with each change reflecting technological developments 
to improve process robustness and to ensure product safety and supply. The last major ETN manufacturing 
change was the introduction of the serum-free process (SFP) (European Medicines Agency/H/C/262/II/83, 
approved on February 28, 2008) (5). The current modifications to the manufacturing process have been 
made to allow for an increase in the yield of drug substance from the same cell bank used in manufacturing 
the current ETN. There were no changes to the drug product formulations as a result of the introduction of 
the new manufacturing process for the drug substance.
Treatment with biological agents, including TNF inhibitors, such as ETN, has proven to be effective by 
reducing disease activity and improving patient quality of life in those who have not responded well 
to conventional disease-modifying antirheumatic drugs (DMARDs) (6-9). TNF inhibitors and other bi-
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Objective: To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured 
using the serum-free, high-capacity manufacturing (SFHCM) process in patients with rheumatoid 
arthritis (RA).
Methods: In this global, multicenter, open-label, single-arm study (NCT02378506), 187 adult patients 
with moderate to severe RA received ETN 50 mg once weekly for 24 weeks manufactured using the 
SFHCM process. Immunogenicity (presence of antidrug antibodies (ADAs) and neutralizing antibod-
ies (NAbs)) was assessed at 12 and 24 weeks. Safety and efficacy were evaluated at 4, 12, and 24 weeks.
Results: Eight (4.5%) patients tested positive for ADA, and there were no NAbs detected at any time 
throughout the study. Ninety (48.1%) patients reported treatment-emergent adverse events (AEs), of 
which 27 (14.4%) reported injection-site reactions, and 43 (23.0%) reported infections. The majority of 
AEs were mild or moderate in severity, and the drug was well tolerated. Throughout the duration of 
the study (week 4 to week 24), there was a progressive increase in the American College of Rheuma-
tology (ACR)-defined responses (ACR20: 55.9%–82.0%, ACR50: 16.1%–57.8%, and ACR70: 3.2%–26.7%) 
from baseline and the proportion of patients achieving low disease activity and remission, with a 
corresponding decrease in measures of disease activity.
Conclusion: The immunogenicity, safety, and efficacy of ETN manufactured using the SFHCM process 
were similar to the current approved ETN formulation. ClinicalTrials.gov registration: NCT02378506.
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ological agents have an inherent capacity to 
be immunogenic. Thus, there is a potential to 
elicit unwanted immune responses, includ-
ing the development of antidrug antibodies 
(ADAs), which may raise safety concerns for 
the patient as well as interfere with drug ef-
ficacy (10-12). Some ADAs do not affect drug 
activity and are designated as non-neutraliz-
ing, whereas other ADAs can become neutral-
izing antibodies (NAbs) negatively affecting 
the ability of the biological agent to bind to 
its target (13). Several studies have demon-
strated that the presence of ADA in patients 
with rheumatoid arthritis (RA) treated with 
TNF inhibitors resulted in subtherapeutic se-
rum drug levels and loss of efficacy, usually 
referred to as secondary failure (14-17). The 
presence of ADA was not linked to reduced 
clinical response in studies reporting ADA 
against ETN (15-17). The presence of ADAs 
may also contribute to the incidence of ad-
verse events (AEs), such as injection-site and 
infusion reactions, thromboembolic events, 
and serum sickness (11, 18, 19).
Studies of the current commercially available 
SFP formulation of ETN reported ADAs in ap-
proximately 5% of patients with RA after 24 
weeks of treatment, none of which were neu-
tralizing (15-17). Although ETN produced by 
the serum-free, high-capacity manufacturing 
(SFHCM) process has no new structural fea-
tures and is, therefore, predicted not to have 
an altered immunogenicity profile compared 
with the current SFP ETN, the present study 
was conducted to demonstrate that it is clini-
cally similar to ETN manufactured by the cur-
rent process so that it may be administered 
safely and with confidence to the patients. 
We report on the immunogenicity, safety, and 
efficacy of ETN manufactured by the SFHCM 
process administered at the same dose (50 
mg once weekly (QW)) as the current com-




This was a global, multicenter, open-label, sin-
gle-arm study (NCT02378506) conducted in 
29 centers in nine countries (Bulgaria, Croatia, 
Germany, Greece, Hungary, Poland, Serbia, 
Slovakia, and South Africa) from April 2015 to 
June 2016. The study was conducted in accor-
dance with the Declaration of Helsinki. Ethics 
committee approvals for this study were re-
ceived from the relevant regulatory bodies in 
each country (see Appendix at the last page). 
Informed consent was obtained from all of the 
patients who participated in the study.
All eligible patients were screened within 4 
weeks prior to the first dose. Patients were ad-
ministered ETN 50 mg QW subcutaneously for 
24 weeks. Immunogenicity (ADAs and NAbs) 
was measured at baseline and subsequent vis-
its at 12 and 24 weeks. The efficacy, safety, and 
patient-reported outcomes were measured at 
baseline and subsequent visits at 4, 12, and 24 
weeks. A safety follow-up was conducted via 
telephone 28-32 days after 24 weeks or early 
withdrawal visit.
Patients
Adult patients with active moderate to se-
vere RA (disease activity score based on 28 
joint count (DAS28) ≥3.2, tender joint count 
(TJC) ≥4, and swollen joint count (SJC) ≥4) at 
screening and baseline visits, who had not 
been treated previously with ETN, and with 
normal laboratory results were enrolled in the 
study. Patients who were previously treated 
with ETN, received methotrexate >25 mg/
week or had a change in dose or route of ad-
ministration of methotrexate within 6 weeks 
of the first study dose, had a dose change in 
permitted conventional synthetic DMARDs 
within 4 weeks of the first study dose, re-
ceived cyclophosphamide, cyclosporine, or 
azathioprine within 6 months of the first study 
dose, received TNF inhibitor or any other bi-
ological treatment for RA within 12 weeks of 
the first study dose, received any biological B 
cell-depleting agent (e.g., rituximab) within 
2 years of the first study dose, received cor-
ticosteroids within 4 weeks of the first study 
dose, received nonsteroidal anti-inflamma-
tory drugs more than the maximum recom-
mended dose, or received live (attenuated) 
vaccines within 4 weeks of the first study dose 
were excluded from the study. Patients with 
serious infections within 4 weeks, with active 
infections at the time of screening or baseline 
visits, with active or latent tuberculosis, or 
with any medical condition that could inter-
fere with the assessments were also excluded.
Assessments
ETN concentration was measured from serum 
samples collected prior to the first dose and af-
ter 12 and 24 weeks of treatment or upon early 
withdrawal, using a validated enzyme-linked 
immunosorbent assay (ELISA). Serum samples 
used to test for ADAs to ETN were collected 
simultaneously in order to minimize the po-
tential drug effect and were assayed using 
the same validated ELISA used throughout 
the development of ETN. During the most 
recent cross-validation, the assay precision 
for the negative control, expressed as the be-
tween-day percent coefficient of variation, was 
20.2%.
Samples were deemed positive if the optical 
density was two times than what was observed 
in the pre-treatment samples. There was no 
distinction between the positive samples of 
different titers. All samples testing positive for 
ADA were subsequently evaluated for the pres-
ence of Nabs using a validated ELISA. During 
the most recent cross-validation, the assay pre-
cision for the negative control was ≤13.3%. All 
assays were conducted by Celerion (formerly 
MDS Pharma Services, Lincoln, NE, USA).
The incidence and severity of all AEs and se-
rious AEs (SAEs) were recorded, and the ab-
normal test findings, laboratory evaluations, 
and vital signs were monitored. The efficacy of 
treatment was determined as 20%, 50%, and 
70% improvements from baseline in the Amer-
ican College of Rheumatology (ACR) criteria for 
RA (ACR20, ACR50, and ACR70, respectively), 
DAS28 by erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP), number of TJC 
and SJC, Physician Global Assessment (PGA), 
Patient Global Assessment (PtGA), Health As-
sessment Questionnaire-Disability Index (HAQ-
DI), patient general health, and patient pain as-
sessed using a Visual Analog Scale (VAS).
Statistical analysis
Approximately 180 patients were enrolled to 
provide 162 evaluable patients. Assuming that 
the true incidence of ETN ADA formation was 
≤5%, the probability of obtaining an estimate 
of >10% was not >0.33%. If the true incidence 
of ETN ADA formation was ≥10%, the proba-
bility of obtaining an estimate of ≤5% was not 
>1.54%. This number of patients would also 
provide 80% probability of observing one or 
more safety events with an incidence of ≥1%. 
Events and response proportions are present-
ed as percentages (%) with 95% confidence 
intervals. For composite endpoints, including 
the DAS28-CRP and ACR responses, missing 
values of component parameters were carried 
forward from the previous visit. There was no 
formal statistical testing planned. A life-table 
estimate of the cumulative incidence of anti-
body formation through 12 and 24 weeks was 
performed to adjust the estimate for incom-
plete data. The life-table analysis accounted for 
when subjects completed the ADA evaluations 
and whether subjects discontinued the study 
early, prior to the protocol-specified 24 weeks 
of the study duration of treatment.
Results
Patients
A total of 188 patients were enrolled in the 
study. Of the patients, 163 (86.7%) completed 
the study (Figure 1). One patient withdrew 
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consent prior to any drug administration. An 
additional 22 patients discontinued during 
the study, with 3 (1.6%) for lack of efficacy, 14 
(7.4%) due to AEs, 2 (1.1%) for protocol devia-
tion, 1 (0.5%) died, 4 (2.1%) for withdrawal of 
consent, and 1 (0.5%) for other reasons. The 
baseline patient characteristics (Table 1) were 
similar to published patient characteristics for 
studies demonstrating ETN efficacy and safety 
in patients with RA (6-9). Overall, 153 (81.8%) 
patients received concomitant methotrexate 
during the study.
Immunogenicity
The median duration of treatment was 23 
(21.6±5.0) weeks. Data on the ADA status 
during the course of the study were missing for 
11 patients, with 10 due to mishandling of the 
baseline sample and 1 withdrew consent at 4 
weeks. The baseline patient characteristics for 
patients testing positive for ADA are compara-
ble to those testing negative (Table 1). Of the 
176 patients for whom immunogenicity data 
were available (at least one ADA assessment), 
8 (4.5%) tested positive for ADA at any time 
throughout the study (Table 2), all of whom 
were receiving concomitant methotrexate. Of 
these 8 patients, 3 (1.7%) tested positive at 12 
weeks (individual ADA titers of 200, 400, and 
400 arbitrary units (AU)/mL), and 5 (2.8%) more 
tested positive at 24 weeks or early termination 
(individual ADA titers of 100, 200, 400, 400, and 
>400 ADA AU/mL). High and low ADA titers 
were not distinguished, as all positive samples 
were subsequently tested, and all were found 
to be negative for NAbs. Since early termina-
tion can occur at any time during the study, 
some patients tested positive for ADA prior 
to 12 weeks. The cumulative incidence rates 
were 3.64% up to 12 weeks and 6.16% up to 24 
weeks using a life-table analysis.
The mean±standard deviation (SD) concen-
trations of ETN at 12 weeks were 1.5±0.2 μg/
mL among patients testing positive for ADA 
(n=3) and 2.3±1.3 μg/mL among those testing 
negative for ADA (n=154; p=0.29). At 24 weeks 
or early termination, the mean±SD concentra-
tions were 1.0±0.5 μg/mL (n=5) and 2.3±1.7 
μg/mL (n=158; p=0.02), respectively.
Safety
Table 3 summarizes all-cause treatment-emer-
gent AEs (TEAEs). A total of 90 (48.1%) patients 
reported 196 TEAEs, 27 (14.4%) patients re-
ported 48 injection-site reactions, 43 (23.0%) 
patients reported 50 investigator-identified 
infections, and 56 (29.9%) patients reported 
98 other AEs. Nine (4.8%) patients reported 
11 SAEs, with lymphadenopathy, acute cardi-
ac failure, metatarsalgia, osteoarthritis, major 
25
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Figure 1. Patient disposition
ADA: antidrug antibody
Table 1. Baseline patient characteristics by ADA status*
 Total (n=187)** ADA+(n=8) ADA−(n=168)
Age (years) 54.2 (12.9) 58.8 (15.0) 54.2 (12.5)
Female, n (%) 159 (85.0) 6 (75.0) 145 (86.3)
Race, n (%)   
White 179 (95.7) 8 (100.0) 160 (95.2)
Black 0 (0.0) 0 (0.0) 0 (0.0)
Asian 4 (2.1) 0 (0.0) 4 (2.4)
Other 4 (2.1) 0 (0.0) 4 (2.4)
Baseline BMI (kg/m2) 27.3 (5.2) 27.2 (6.2) 27.5 (5.3)
Disease duration (years) 8.0 (7.2) 10.3 (13.0) 7.8 (7.0)
Prior medications, n (%)   
Non-biological DMARDs 96 (51.3) 2 (25.0) 87 (51.8)
Biological DMARDs 29 (15.5) 3 (37.5) 26 (15.5)
Corticosteroids 97 (51.9) 0 (0.0) 89 (53.0)
Methotrexate 169 (90.4) 8 (100.0) 152 (90.5)
RF positive, n (%) 116 (62.0) 3 (37.5) 108 (64.3)
Anti-CCP positive, n (%) 126 (67.4) 3 (37.5) 117 (69.6)
ESR (mm/h) 36.1 (22.1) 36.0 (26.4) 34.9 (21.6)
CRP (mg/L) 11.2 (16.0) 17.2 (22.1) 10.6 (14.9)
TJC 14.2 (6.0) 16.0 (6.3) 13.9 (6.1)
SJC 10.9 (5.2) 13.2 (7.1) 10.6 (5.1)
DAS28-ESR 6.2 (0.9) 6.5 (0.9) 6.1 (0.9)
DAS28-CRP 5.4 (0.9) 5.9 (1.0) 5.3 (0.9)
*Data were presented as mean (SD), unless otherwise stated 
**The total numbers do not add up to the other two columns because the ADA data for 11 patients were not available 
ADA: antidrug antibody, BMI: body mass index, CCP: cyclic citrullinated peptide, CRP: C-reactive protein, DAS28: disease 
activity score based on 28 joint count, DMARD: disease-modifying antirheumatic drug, ESR: erythrocyte sedimentation rate, RF: 
rheumatoid factor, SD: standard deviation, SJC: swollen joint count, TJC: tender joint count
depression, ureteric calculus, urticaria, deep 
vein thrombosis, diverticulitis, pneumonia, and 
wound infection for each. Six (3.2%) patients 
reported severe AEs, with urticaria, lymphade-
nopathy, acute cardiac failure, retinal detach-
ment, back pain, and allergic dermatitis for 
each. Fourteen (7.5%) patients experienced an 
AE leading to discontinuation, with three due 
to injection-site reactions, two due to infec-
tions, and one each due to urticaria, lymphade-
nopathy, acute cardiac failure, macular rash, 
depression, allergic dermatitis, pruritic rash, 
thrombocytopenia, and one worsening of RA, 
and one death was due to acute heart failure. 
Fifty-two (27.8%) patients experienced an AE 
considered by the investigator to be drug-re-
lated. There were no TEAEs of opportunistic 
infections, malignancies, demyelinating disor-
ders, or prespecified events of clinical impor-
tance reported. The majority of AEs were mild 
or moderate in severity.
Efficacy
Overall, the proportions of patients achieving 
ACR20, ACR50, and ACR70 increased progres-
sively over time (Figure 2a), accompanied by a 
decrease in DAS28-ESR and DAS28-CRP scores 
(Figure 2b) and an increase in the proportion 
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Table 2. Summary of the incidence of patients developing ADA against ETN by methotrexate 
treatment status*
 All patients No methotrexate Methotrexate 
 (n=176) (n=16) (n=160)
Total 4.5 (2.2-8.4) 0.0 (0.0-14.3) 5.0 (2.4-9.2)
At 12 weeks 1.9 (0.5-5.0) 0.0 (0.0-16.2) 2.1 (0.6-5.5)
At 24 weeks or early termination 2.9 (1.1-6.1) 0.0 (0.0-14.3) 3.1 (1.2-6.8)
At any time 4.5 (2.2-8.4) 0.0 (0.0-14.3) 5.0 (2.4-9.2)
*Data were presented as percentage (%, 95% CI) 
ADA: antidrug antibody, CI: confidence interval, ETN: etanercept
Figure 2. a-c. Clinical responses
Proportions of patients achieving ACR20, ACR50, and ACR70 (b); DAS28-ESR and DAS28-CRP scores (b); proportions of patients achieving LDA and remission according 
to the DAS28-ESR and DAS28-CRP criteria at 24 weeks (c). For composite measures, missing component values were imputed using the last observation carried forward
ACR20; ACR50; ACR70: American College of Rheumatology criteria for RA, CRP: C-reactive protein, DAS28: disease activity score based on 28 joint count, ESR: erythrocyte 
sedimentation rate, LDA: low disease activity, SD: standard deviation
a b c
Table 3. Total
  Injection-site 
 Total reactions Infections All other
Total no. of AEs 196 48 50 98
Patients with AEs 90 (48.1) 27 (14.4) 43 (23.0) 56 (29.9)
Patients with SAEs 9 (4.8) 0 (0.0) 3 (1.6) 8 (4.3)
Patients with severe AEs 6 (3.2) 0 (0.0) 0 (0.0) 6 (3.2)
Patients discontinuing due to AEs 14 (7.5) 3 (1.6) 2 (1.1) 9 (4.8)
Patients with temporary discontinuation due to AEs 21 (11.2) 0 (0.0) 18 (9.6) 5 (2.7)
*Data were presented as n (%) 
AE: adverse event, SAE: serious adverse event, TEAE: treatment-emergent adverse event
Figure 3. a-c. Clinical responses by the ADA status
Proportions of ADA+ and ADA- patients achieving ACR20, ACR50, and ACR70 (a); DAS28-ESR and DAS28-CRP scores in ADA+ and ADA- patients (b); proportions of 
ADA+ and ADA- patients achieving LDA and remission according to the DAS28-ESR and DAS28-CRP criteria at 24 weeks (c). For composite measures, missing com-
ponent values were imputed using the last observation carried forward
ACR20; ACR50; ACR70: American College of Rheumatology criteria for RA, ADA: antidrug antibody, CRP: C-reactive protein, DAS28: disease activity score based on 28 
joint count, ESR: erythrocyte sedimentation rate, LDA: low disease activity, SD: standard deviation
a b c
of patients achieving low disease activity (LDA; 
<3.2) and remission (<2.6) according to both 
DAS28-ESR and DAS28-CRP criteria (data not 
shown). At 24 weeks, 44.4% (72/162) and 66.0% 
(107/162) of patients achieved LDA, as mea-
sured via DAS28-ESR and DAS28-CRP, respec-
tively, and 29.6% (48/162) and 48.1% (78/162) 
achieved disease remission (Figure 2c).
When analyzed by the ADA status, a progres-
sive increase in ACR20 and ACR50 responses 
was observed over time for patients testing 
positive and negative for ADA (Figure 3a). How-
ever, there was no patient testing positive for 
ADA who achieved an ACR70 response at any 
time point (Figure 3a). DAS28-ESR and DAS28-
CRP scores decreased progressively over time 
in both patients testing positive and negative 
for ADA (Figure 3b). At 24 weeks, 50.0% (2/4) 
of patients testing positive for ADA achieved 
LDA, as measured via DAS28-ESR and DAS28-
CRP, compared with 44.3% (66/149) and 67.1% 
(100/149) of patients testing negative for ADA, 
respectively (Figure 3c). Furthermore, 25.0% 
(1/4) and 50.0% (2/4) of patients testing pos-
itive for ADA achieved disease remission, as 
measured via DAS28-ESR and DAS28-CRP, re-
spectively, compared with 30.2% (45/149) and 
49.7% (74/149) of patients testing negative for 
ADA (Figure 3c).
Over the course of the study, there were con-
sistent decreases in TJC and SJC, as well as 
decreases in scores for PGA, PtGA, HAQ-DI, pa-
tient’s assessment of general health, and pain 
VAS (Figure 4).
Discussion
The present study assessed the immunogenic-
ity, safety, and efficacy of ETN manufactured 
using the SFHCM process in 187 subjects with 
moderate to severe RA during 24 weeks of ad-
ministration. We compared the immunogenic-
ity, safety, and efficacy of ETN manufactured by 
the SFHCM process with historical results. The 
current commercially available ETN induces 
a significantly lower immunogenic response, 
with the development of fewer ADAs, than 
anti-TNF monoclonal antibodies (20). Further-
more, treatment with the current commercial 
formulation of ETN has not been associated 
with the development of detectable NAbs (7, 
16).
The incidence of 8 (4.5%) patients developing 
ADA is consistent with findings for ETN man-
ufactured using the current manufacturing 
process, which report up to 5% of patients 
developing ADA (7, 21). It is not surprising that 
all eight patients were receiving concomitant 
methotrexate, since >81% of patients were in 
this group. Importantly, from a clinical efficacy 
point of view, none of the patients treated in 
the present study developed NAbs. In addi-
tion, importantly, the ETN used in the present 
study was well tolerated, with most of the AEs 
being mild or moderate in severity. These data 
are also consistent with published studies (7, 
11, 14-17). These results confirmed that ETN 
manufactured by the SFHCM process retained 
low immunogenicity potential and a favorable 
risk-to-benefit ratio when compared with the 
current commercially available ETN.
The efficacy of ETN manufactured using the 
SFHCM process, shown as improvements in 
ACR response, DAS28 score, and other effica-
cy parameters, was similar to that observed in 
controlled clinical trials with similar enrollment 
criteria (6-9). However, the presence of ADAs 
appeared to reduce the therapeutic response 
to ETN as measured by ACR, as no patients who 
developed ADAs achieved an ACR70 response 
at any time point, unlike the patients who did 
not develop ADAs. There were no significant 
differences in decreased disease activity, as 
measured using DAS28, between patients who 
developed ADAs and those who did not. How-
ever, it is important to note that no formal effi-
cacy comparisons were planned or performed 
between patients with and without ADAs due 
to the small number of patients who were ex-
pected to develop ADAs after treatment with 
ETN that was manufactured using the SFHCM 
process. Consistent with published studies, 
ETN manufactured in this SFHCM process was 
well tolerated (6-9). Our study was conducted 
in a population of patients with characteristics 
that have been well established for the evalua-
tion of new biological agents for the treatment 
of RA, including a relatively low proportion 
(15.5%) of patients exposed to prior biological 
DMARDs and a high proportion of patients re-
ceiving concomitant glucocorticoids (51.9%) 
and methotrexate (90.4%). In addition, the 
single-arm, open-label study design must be 
taken into consideration when interpreting 
the efficacy results. Finally, although the ELI-
SA methodology used to measure ETN levels 
and ADA/NAb titers is widely used and recog-
nized as reliable, it does have some limitations, 
including non-specific binding and failure to 
detect low-affinity antibodies (22). However, 
we believe that the comparison of ETN con-
centrations and ADA frequency results from 
the present study with those from previous 
ETN studies is justified because the same ELISA 
methodology has been used throughout the 
development of ETN.
When compared with historical data on the 
current commercially available ETN, this sin-
gle-arm, open-label study with ETN manufac-
tured using the SFHCM process has succeed-
ed in meeting all the objectives pertaining to 
immunogenicity, safety, and efficacy. Changes 
in the manufacturing processes are needed to 
take advantage of new technologies and to 
maintain adequate supplies of medications for 
patients. Strictly regulated revision of changes 
in the manufacturing process of ETN, as with 
other therapeutic agents, is a common part of 
the ongoing aim to keep an established medi-
cine safe and efficacious while improving man-
ufacturing. This is important for clinical consis-
tency so that both physicians and patients can 
be confident about the reproducibility and re-
liability of the safety and efficacy results when 
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Figure 4. Summary of efficacy assessments at 24 weeks
HAQ-DI: Health Assessment Questionnaire-Disability Index, PGA: Physician Global Assessment, PtGA: Patient Global Assessment, SD: standard deviation, SJC: swollen 
joint count, TJC: tender joint count, VAS: Visual Analog Scale
prescribing or receiving ETN manufactured via 
a new process.
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Appendix. 
Table A1. List of IEC/IRB Approvals by Country and Study Site
Country Study Site Number IEC or IRB Approval Date
Bulgaria 1052 Republic of Bulgaria Ministry of Health 25-MAR-15 
  Ethics Committee for Multicenter Trials 
  Sofia, BULGARIA
 1061 Republic of Bulgaria Ministry of Health 10-JUN-15 
  Ethics Committee for Multicenter Trials 
  Sofia, BULGARIA
 1071 Republic of Bulgaria Ministry of Health 10-JUN-15 
  Ethics Committee for Multicenter Trials 
  Sofia, BULGARIA
 1072 Republic of Bulgaria Ministry of Health 25-MAR-15 
  Ethics Committee for Multicenter Trials 
  Sofia, BULGARIA
Croatia 1062 Central Ethics Committee 24-FEB-15 
  Agency For Medicinal Products And Medical Devices 
  Zagreb, CROATIA
 1094 Central Ethics Committee 24-FEB-15 
  Agency For Medicinal Products And Medical Devices 
  Zagreb, CROATIA
 1096 Central Ethics Committee 
  Agency For Medicinal Products And Medical Devices 16-APR-15 
  Zagreb, CROATIA
Germany 1053 Ethikkommission der Medizinischen Hochschule Hannover 7-APR-15 
  Hannover, GERMANY
 1054 Ethikkommission der Medizinischen Hochschule Hannover 7-APR-15 
  Hannover, GERMANY
 1073 Ethikkommission der Medizinischen Hochschule Hannover 7-APR-15 
  Hannover, GERMANY
 1091 Ethikkommission der Medizinischen Hochschule Hannover 7-APR-15 
  Hannover, GERMANY
 1092 Ethikkommission der Medizinischen Hochschule Hannover 7-APR-15 
  Hannover, GERMANY
Greece 1004 National Ethics Committee 31-JUL-15 
  Athens, GREECE
 1007 National Ethics Committee 5-MAY-15 
  Athens, GREECE
 1081 National Ethics Committee 5-MAY-15 
  Athens, GREECE
Hungary 1005 Medical Research Council 22-JAN-15 
  Ethics Committee for Clinical Pharmacology 
  Budapest, HUNGARY
 1059 Medical Research Council  22-JAN-15 
  Ethics Committee for Clinical Pharmacology 
  Budapest, HUNGARY
 1064 Medical Research Council 22-JAN-15 
  Ethics Committee for Clinical Pharmacology 
  Budapest, HUNGARY
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Appendix. 
Table A1. List of IEC/IRB Approvals by Country and Study Site (Continued)
Country Study Site Number IEC or IRB Approval Date
Poland 1065 Komisja Bioetyczna przy Okregowej 17-DEC-14 
  Radzie Lekarskiej Wielkopolskiej Izby Lekarskiej 
  Poznan, POLAND
 1066 Komisja Bioetyczna przy Okregowej 25-MAR-15 
  Radzie Lekarskiej Wielkopolskiej Izby Lekarskiej 
  Poznan, POLAND
 1074 Komisja Bioetyczna przy Okregowej 2-JUN-15 
  Radzie Lekarskiej Wielkopolskiej Izby Lekarskiej 
  Poznan, POLAND
 1077 Komisja Bioetyczna przy Okregowej 25-MAR-15 
  Radzie Lekarskiej Wielkopolskiej Izby Lekarskiej 
  Poznan, POLAND
Serbia 1067 Ethics Committee of the Institute of Rheumatology 8-DEC-14 
  Belgrade, SERBIA
 1078 Ethics Committee of the Institute of Rheumatology 8-DEC-14 
  Belgrade, SERBIA
Slovakia 1015 Eticka komisia 12-JAN-15 
  Urad Presovskeho samospravneho kraja 
  Presov, SLOVAKIA
  Eticka komisia 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA
 1026 Eticka komisia 25-NOV-14 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA
 1028 Eticka komisia 25-NOV-14 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA
  Eticka komisia 
  Bratislavsky samospravny kraj  
  Bratislava, SLOVAKIA
 1029 Eticka komisia 11-DEC-14 
  Trnavsky samospravny kraj 
  Trnava, SLOVAKIA
  Eticka komisia 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA
 1080 Nezavisla eticka komisia  12-JAN-15 
  Banskoby strickeho samospravneho kraja 
  Banska Bystrica, SLOVAKIA
  Eticka komisia 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA 
 1088 Eticka komisia 11-DEC-14 
  Urad Zilinskeho samospravneho kraja 
  Zilina, SLOVAKIA
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Appendix. 
Table A1. List of IEC/IRB Approvals by Country and Study Site (Continued)
Country Study Site Number IEC or IRB Approval Date
  Eticka komisia 
  Trnavsky samospravny kraj 
  Trnava, SLOVAKIA 
South Africa 1050 Pharma Ethics Independent Research Ethics committee 4-FEB-15 
  Pretoria, SOUTH AFRICA
 1068 University of the Witwatersrand, Johannesburg 13-FEB-15 
  Human Research Ethics Committee: (Medical) 
  Johannesburg, SOUTH AFRICA
 1069 Pharma Ethics Independent Research Ethics committee 4-FEB-15 
  Pretoria, SOUTH AFRICA
IEC: Independent Ethics Committee; IRB: Institutional Review Board
